Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 16/20 | 0.69 |
| ▸ | PIK3CG | P48736 | 9/20 | 0.69 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.69 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.61 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.60 |
| ▸ | MTOR | P42345 | 2/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4134574 | 0.83 | PIK3CA (0.63) | PIK3CAPIK3CGPIK3CBPDE10AMTOR | |
| SCHEMBL1309874 | 0.83 | PIK3CA (0.71) | PIK3CAPIK3CGPIK3CBPIK3CDMTOR | |
| SCHEMBL3552584 | 0.83 | PIK3CA (0.74) | PIK3CAPIK3CGPIK3CBPDE10AMTOR | |
| SCHEMBL4133831 | 0.82 | PIK3CA (0.72) | PIK3CAPIK3CGPIK3CBPIK3CDMTOR | |
| SCHEMBL13800978 | 0.81 | PIK3CA (0.71) | PIK3CAPIK3CGPIK3CBPIK3CDMTOR | |
| SCHEMBL4138270 | 0.80 | ALDH1A1 (0.69) | PIK3CAPIK3CGPIK3CBPIK3CDMTOR | |
| SCHEMBL3550609 | 0.80 | PIK3CA (0.55) | PIK3CAPIK3CGPIK3CBPDE10AFFAR1 | |
| SCHEMBL4133828 | 0.78 | PIK3CA (0.68) | PIK3CAPIK3CGPIK3CBPIK3CDMTOR | |
| SCHEMBL3553118 | 0.78 | PIK3CA (0.59) | PIK3CAPIK3CGPIK3CBPDE10APIK3CD | |
| SCHEMBL4138044 | 0.77 | PIK3CA (0.73) | PIK3CAPIK3CGPIK3CBPDE10APIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | US | claimed |
| EP-1945627-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2008-07-23 | — | — | EP | claimed |
| WO-2007042806-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2007-04-19 | — | — | WO | claimed |
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | US | disclosed |
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | US | disclosed |
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | US | disclosed |
| WO-2007042806-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | NR3C1, NR4A3, NR4A1 | PIK3CA 137/4885PIK3CG 618/4885PIK3CB 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.